SCYX241220P2500
- 1.10
- 0.000.00%
Scynexis Newsroom
US Manufacturing Index Rises To 43, Highest Since 2020
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK) and SCYNEXIS (SCYX)
SCYNEXIS's Strong Financial Position and Strategic Advancements Drive Buy Rating
Scynexis Reports Q3 EPS (6c), Consensus (7c)
Express News | Scynexis Q3 Basic EPS USD -0.06
Express News | Scynexis Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Press Release: SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Scynexis 3Q Rev $660,000 >SCYX
Express News | Scynexis Q3 EPS USD -0.06
Express News | Scynexis- Entered Into Controlled Equity Offering Sales Agreement, May Offer & Sell Shares of Common Stock for $50 Mln From Time to Time
Scynexis | 10-Q: Q3 2024 Earnings Report
Investors in SCYNEXIS (NASDAQ:SCYX) Have Unfortunately Lost 89% Over the Last Five Years
Earnings Preview: Scynexis to Report Financial Results Post-market on October 18
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024
SCYNEXIS Advances Antifungal Treatments, Strengthens Financial Outlook
SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference
SCYNEXIS Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Earnings Flash (SCYX) SCYNEXIS Posts Q2 Revenue $736,000
Express News | Scynexis Reports Second Quarter 2024 Financial Results and Provides Corporate Update